DR Program

Evidence: Diabetic Retinopathy Program

What we can share publicly about our DR research

Information presented represents historical observations and preclinical research. Results may not be generalizable and do not predict future clinical outcomes.

Public Summary

Scientific Rationale
  • Research indicates that lipoxins (like LXA4) and other specialized pro-resolving lipid mediators play important roles in resolving inflammation
  • Studies suggest that LXA4, BDNF, AA, and DHA levels may be reduced in patients with diabetes and diabetic retinopathy
  • LXA4 is derived from arachidonic acid (AA) and has been shown in research to have anti-inflammatory properties
  • The retina is rich in lipids, particularly DHA, making lipid-based approaches scientifically relevant
Mechanism Research
  • Research has explored how LXA4 may block inflammatory pathways including NFkB
  • Studies suggest potential effects on VEGF, angiopoietin-2, and IL-6 signaling
  • BDNF support as a neuroprotective strategy has been investigated in retinal research
  • The goal of inhibiting VEGF production (vs. neutralization) represents a distinct mechanistic approach
Development Context
  • Anti-VEGF monoclonal antibody injections are the current standard of care
  • These require repeated intravitreal injections over time
  • There is interest in approaches that might reduce treatment burden
  • Eye-drop formulations remain an area of research interest in ophthalmology

Available upon request (data-room)

For qualified parties under appropriate agreements

Detailed composition and formulation informationUpon Request
Preclinical study protocols and interim findingsUpon Request
Patent documentationUpon Request
Development timeline and milestonesUpon Request
Scientific literature supporting the approachUpon Request
Comparison with existing therapies (detailed analysis)Upon Request

Important Notice: This website describes investigational research. Our programs (ARKA-101, SURYA-101) are not approved for clinical use. Content is educational and for partnership discussions, not medical advice.

Urgent symptoms: If you experience sudden vision changes, flashes, floaters, or vision loss, seek immediate medical care. This is a medical emergency.